Large-Scale Study Confirms Statin-Related Serious Muscle Disorders Are Extremely Rare

Researchers analyzed electronic health records of 1.7 million English adults—men >= 50 years and women >= 60 years—registered 1998-2018. A validated model predicted 1-, 5-, and 10-year risk of hospitalization or death from serious muscle disorders. Fewer than 1 % had a projected 10-year risk above 10 %, and only 0.04 % were in the highest-risk group. Overall incidence was extremely low. Statins can lower LDL cholesterol by up to 60 % and markedly reduce cardiovascular events.

HealthLine

Statins can lower low-density lipoprotein cholesterol by up to 60 % and reduce heart disease risk. However, concerns about muscle side effects have lowered prescription fill rates. In the United States, fewer than half of the estimated 50 million eligible adults receive statins, and about one-third of prescriptions are never filled.

HealthLine

The cohort included men >= 50 years and women >= 60 years from the Clinical Practice Research Datalink (1998-2018). Researchers adjusted for competing mortality and validated the model across multiple horizons, focusing on individuals eligible for statin therapy regardless of actual use at the index date.

HealthLine

Study authors warned that misattributed concerns about statin side effects have limited optimal use and may increase cardiovascular morbidity. Yu-Ming Ni, MD, said the data provide personalized risk information for treatment decisions. Cheng-Han Chen, MD, said the findings confirm statins’ safety and efficacy. Roger Blumenthal, MD, AHA 2026 Dyslipidemia Guideline chair, emphasized that LDL-cholesterol reduction benefits far outweigh the minimal muscle-related risk.

HealthLine

Despite the low reported incidence, patients and physicians continue to cite muscle pain and rare severe toxicity as reasons for discontinuing or avoiding statins, arguing that even infrequent adverse events can erode adherence.

HealthLine

The article presents both a “less than 1 %” estimate and a precise “0.04 %” figure for high-risk individuals, indicating a minor discrepancy. The English-based cohort also limits direct applicability to more diverse U.S. populations.

HealthLine

• “When you look broadly across all people currently on statins, the rate of side effects is very low,” — Yu-Ming Ni, MD, cardiologist and lipidologist, MemorialCare Heart and Vascular Institute

HealthLine

• “Clinical treatment decision making can be better informed by personalized risk information about treatment outcomes, including both benefits and harms,” — Study authors

HealthLine

• “These results confirm our understanding that statins are a very safe and effective medication for treatment of heart disease,” — Cheng-Han Chen, MD, interventional cardiologist, MemorialCare Saddleback Medical Center

HealthLine

• “The incidence of muscle side effects with statin therapy is extremely low. The benefits of lowering LDL-cholesterol are clear,” — Roger Blumenthal, MD, Chair, AHA 2026 Dyslipidemia Guideline writing committee

HealthLine

The authors hope the model will help convince patients and clinicians of the favorable risk-benefit balance of statins, thereby supporting shared decision-making in cardiovascular prevention.

HealthLine